Cobicistat

Evidence Level: L5

Predicted Indications: 3

Cobicistat

Pharmacist Assessment Report

Cobicistat: From HIV Infection to Simian Immunodeficiency Virus Infection

One-Sentence Summary

Cobicistat is a pharmacokinetic booster (a CYP3A inhibitor) originally used in HIV infection and AIDS treatment regimens. The TxGNN model predicts it may be effective for simian immunodeficiency virus infection, but there are currently 0 clinical trials and 0 publications supporting this direction, so the prediction rests on model output alone.

Quick Overview

Item	Content
Original Indication	HIV infection / AIDS
Predicted New Indication	Simian immunodeficiency virus infection
TxGNN Prediction Score	0.9992
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 4 of 4)
Number of DINs	4 (marketed: 4)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, cobicistat is a CYP3A inhibitor used as a pharmacokinetic booster. It has no intrinsic antiviral activity. It raises blood levels of co-administered antiretrovirals that are CYP3A substrates. Its role in HIV treatment is therefore supportive, not directly antiviral.

Simian immunodeficiency virus (SIV) is a lentivirus closely related to HIV, so a conceptual link to the approved HIV indication exists. The high score (0.9992) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. Any benefit would depend on pairing cobicistat with a suitable antiretroviral, and SIV is mainly a veterinary or preclinical-model indication rather than a human therapeutic target.

Two other predictions were also generated:

Feline acquired immunodeficiency syndrome (score 0.9992): This has the same score as SIV, which comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. It is veterinary, and any use would need species-specific pharmacokinetic validation.
Neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter (score 0.9991): No plausible link to CYP3A inhibition is evident. The score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02426501	PREZCOBIX	Not specified	Not specified
02473720	SYMTUZA	Not specified	Not specified
02449498	GENVOYA	Not specified	Not specified
02397137	STRIBILD	Not specified	Not specified

All four authorizations are currently valid.

Safety Considerations

Drug Interactions: The interaction screening returned 100 interactions in total. This is a large burden, consistent with strong CYP3A inhibition. The first 20 listed include:
- Major: loperamide, triamcinolone, cisapride, budesonide
- Moderate: hydrocortisone, betamethasone, dexamethasone (including nasal and ophthalmic forms), aprepitant, clotrimazole, clarithromycin, metoclopramide, repaglinide, fenfluramine, dexfenfluramine, prednisolone (ophthalmic), budesonide (nasal), hydrocortisone (ophthalmic)
- Minor: prucalopride
The large interaction burden is an added concern for any new population, especially pediatric or neurological patients.

Please refer to the package insert for other safety information, including warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported only by the model score, with no clinical trials or publications. Cobicistat has no antiviral activity of its own, and the top two predicted indications are veterinary or preclinical-model diseases outside the scope of human repurposing. The third prediction has no biological rationale.

To proceed, the following is needed:

Package insert warnings and contraindications from Health Canada (a blocking gap for safety screening)
Detailed mechanism of action data
Independent mechanistic or preclinical evidence for any predicted indication
For SIV or feline indications, species-specific pharmacokinetic validation and a defined co-administered antiretroviral
A review of the high-scoring rare neurodevelopmental prediction for biological plausibility before any further work
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.